Harpoon Therapeutics, Inc.

NasdaqCM:HARP 株式レポート

時価総額:US$492.3m

Harpoon Therapeutics 将来の成長

Future 基準チェック /26

Harpoon Therapeutics is forecast to grow earnings and revenue by 10.6% and 35.3% per annum respectively. EPS is expected to grow by 25.7% per annum. Return on equity is forecast to be -220.2% in 3 years.

主要情報

10.6%

収益成長率

25.7%

EPS成長率

Biotechs 収益成長27.1%
収益成長率35.3%
将来の株主資本利益率-220.2%
アナリストカバレッジ

Good

最終更新日11 Mar 2024

今後の成長に関する最新情報

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

業績と収益の成長予測

NasdaqCM:HARP - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202647-76-67-945
12/31/202523-67-54-648
12/31/202421-56-33-518
12/31/202338-26-16-408
9/30/202337-30-69-69N/A
6/30/202347-40-77-77N/A
3/31/202335-59-84-83N/A
12/31/202232-68-90-89N/A
9/30/202232-71-88-88N/A
6/30/202223-76-84-84N/A
3/31/202221-75-129-129N/A
12/31/202124-117-122-122N/A
9/30/202127-107-121-120N/A
6/30/202126-103-114-113N/A
3/31/202123-99-10-9N/A
12/31/202017-50-9-9N/A
9/30/202012-533940N/A
6/30/202010-554043N/A
3/31/20208-55-11-8N/A
12/31/20196-56-6-3N/A
9/30/20195-51-46-43N/A
6/30/20194-42-41-39N/A
3/31/20194-36-33-32N/A
12/31/20185-27-28-27N/A
9/30/20184-23-9-8N/A
12/31/20171-17-12N/A

アナリストによる今後の成長予測

収入対貯蓄率: HARP is forecast to remain unprofitable over the next 3 years.

収益対市場: HARP is forecast to remain unprofitable over the next 3 years.

高成長収益: HARP is forecast to remain unprofitable over the next 3 years.

収益対市場: HARP's revenue (35.3% per year) is forecast to grow faster than the US market (8.1% per year).

高い収益成長: HARP's revenue (35.3% per year) is forecast to grow faster than 20% per year.


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: HARP is forecast to be unprofitable in 3 years.


成長企業の発掘